Oura’s recent decision to indefinitely postpone its planned IPO, originally targeting a $15–$15.6 billion fully diluted valuation at $40–$44 per share, has driven the dominant market-implied probability of no listing before January 2027. The company cited broader IPO market uncertainty in late September despite multiple-times oversubscribed demand and cornerstone interest from investors including Eli Lilly and Dragoneer. Oura’s underlying momentum—74% year-over-year revenue growth to $1.21 billion in the first nine months of fiscal 2026, projected 90% full-year expansion, and paid membership rising to 5.7 million—supports a prior $11 billion private valuation but does not offset near-term listing risks. Traders are pricing in delayed resolution until clearer market conditions emerge.